A clinical trial involving insulin aspart was listed as recruiting on October 29, 2026. The study, registered as NCT06547619, is titled "Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM." It is classified as an early phase 1 trial. The trial status is currently recruiting, meaning participant enrollment is ongoing. No results have been posted for this study at this time. The trial appears to examine factors related to microvascular dysfunction following gestational diabetes mellitus, with insulin aspart included as part of the study context. As an early phase 1 study, the trial is in its initial stages of investigation. No efficacy or safety outcomes have been reported as part of this update. Insulin aspart remains an approved compound, and this listing reflects only the current recruitment status of the trial, not any findings. Readers interested in the background and general use of insulin aspart can consult the compound overview for additional context.
Insulin Aspart Featured in New Early Phase 1 Trial on Microvascular Health
See the full insulin aspart overview
Source: https://clinicaltrials.gov/study/NCT06547619